🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12043607

HDAC inhibitors and therapeutic use thereof

Tango Therapeutics, Inc. · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043610

Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement

BioCryst Pharmaceuticals, Inc. · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12042487

Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

ARCUTIS BIOTHERAPEUTICS, INC. · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12043629

RIP1K inhibitors

Rigel Pharmaceuticals, Inc. · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12042543

Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste h

Northwestern University · Granted Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12029777

Serine proteinase inhibitors: Serp-1 and Serp-1 RCL-derived peptides effect on microbiome

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12029788

Methods for increasing lean body mass with an exercise regimen and a GDF8 inhibitor that i

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12030896

PIKfyve inhibitors

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12030897

Pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and applica

Medshine Discovery Inc. · Granted Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12024509

Therapeutic compounds as inhibitors of the orexin-1 receptor

C4X Discovery Limited · Granted Tue Jul 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12018057

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Protagonist Therapeutics, Inc. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12018043

CD73 inhibitors

ORIC PHARMACEUTICALS, INC. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12018259

Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibito

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12018027

Macrocyclic derivatives acting as XIa factor inhibitor

China Resources Biopharmaceutical Company Limited · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12018017

Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

Enanta Pharmaceuticals, Inc. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12016860

Combination therapies with Cbl-b inhibitor compounds

NURIX THERAPEUTICS, INC. · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12016835

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12012467

Small molecule DCN1 inhibitors and therapeutic methods using the same

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jun 18 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12005127

DNA-PK inhibitors

Vertex Pharmaceuticals Incorporated · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12006355

Nanobodies against cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory f

The Regents of the University of California · Granted Tue Jun 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11999753

Tetrahydropyridopyrimidine pan-KRas inhibitors

Mirati Therapeutics, Inc. · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11999747

Furoquinolinediones as inhibitors of TDP2

The United States of America as Represented by the Secretary, Dept. of Health and Human Services · Granted Tue Jun 04 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11993594

IRAK inhibitors and method for making and using

Rigel Pharmaceuticals, Inc. · Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11993603

Preparation for 6-amino-1H-pyrazolo[3,4-d]pyrimidine-based JAK kinase inhibitor and applic

CHINA PHARMACEUTICAL UNIVERSITY · Granted Tue May 28 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted